In particular, low dose IL-2 administration is under active clinical investigation for the therapeutic effects in type 1 diabetes, hepatitis C virus-induced vasculitis, alopecia areata, systemic lupus erythematosus and chronic graft versus host disease [9,55,56]. This evidence concerns the gene IL2 and systemic lupus erythematosus.